Safety, efficacy, and tolerabilit…lled, phase 3 trial.

🔬 Peer-reviewed

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.

Howard JF Jr, Bril V, Vu T, Karam C, Peric S et al.

The Lancet. Neurology · 2021

Ingredients studied

Mannan →

Findings

PubMed study on Mannan in cosmetics/dermatology

Design

Randomized Controlled Trial

Evidence

Moderate

Journal

The Lancet. Neurology